Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 79

Sort by

Sort Order Select

Journal Articles

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

Blood (2025) 146 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2025-LBA-6

Published: 2025

Journal Articles

An open-label rollover study to assess the long-term safety of ixazomib

Sebastian Grosicki, Markus Hansson, Meletios Dimopoulos, Tadao Ishida, Vishal Kukreti, Dok Hyun Yoon, Wee-Joo Chng, Oliver Bechter, Xuejun Peng, Paul Richardson

Blood (2025) 146 (Supplement 1): 7547.

https://doi.org/10.1182/blood-2025-7547

Published: 2025

Journal Articles

Nanopore sequencing-based profiling of circular RNAs in multiple myeloma uncovers circNFATC3 as a promising prognostic biomarker

Maria Papatsirou, Christos Kontos, Ioannis Ntanasis-Stathopoulos, Panagiotis Tsiakanikas, Christine-Ivy Liacos, Maria Gavriatopoulou, Efstathios Kastritis, Meletios Dimopoulos, Jerome Moreaux, Andreas Scorilas, Evangelos Terpos

Blood (2025) 146 (Supplement 1): 7452.

https://doi.org/10.1182/blood-2025-7452

Published: 2025

Journal Articles

Novel criteria for evaluating early treatment response with whole body magnetic resonance imaging and prognostic implications in patients with newly diagnosed multiple myeloma

Ioannis Ntanasis-Stathopoulos, Vassilis Koutoulidis, Maria Gavriatopoulou, Maria Douka, Panagiotis Malandrakis, Charalampos Filippatos, Vasiliki Spiliopoulou, Foteini Theodorakakou, Despina Fotiou, Ilias Katsadouros, Eirini Solia, Magdalini Migkou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, Lia-Angela Moulopoulos, Meletios Dimopoulos, Evangelos Terpos

Blood (2025) 146 (Supplement 1): 5765.

https://doi.org/10.1182/blood-2025-5765

Published: 2025

Journal Articles

Impact of tumor burden on the risk of cytokine release syndrome (CRS) in patients with multiple myeloma treated with elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) in the MagnetisMM-6 trial

Cyrille Touzeau, Hanlon Sia, Sebastian Grosicki, Paz Ribas, Carmine Liberatore, Paula Rodriguez-Otero, Suzanne Trudel, Takashi Ikeda, Antonio Lazzaro, Karen Gogat-Marchant, Sharon T. Sullivan, Domenico Cieri, Eric Leip, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 2283.

https://doi.org/10.1182/blood-2025-2283

Published: 2025

Journal Articles

Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients

Enrique Ocio, Aurore Perrot, Jesus San-Miguel, Lionel Karlin, Joaquin Martinez-Lopez, Sara Bringhen, Paula Rodriguez-Otero, Mohamad Mohty, Robert Orlowski, Meletios Dimopoulos, Xavier Leleu, María-Victoria Mateos, Philippe Moreau, Sandrine Macé, Ecrem Kodas, Christine Tekle, Umer Khan, Corina Oprea, Thierry Facon

Blood (2025) 146 (Supplement 1): 2267.

https://doi.org/10.1182/blood-2025-2267

Published: 2025

Journal Articles

Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study

Blood (2025) 146 (Supplement 1): 2264.

https://doi.org/10.1182/blood-2025-2264

Published: 2025

Journal Articles

Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age

Blood (2025) 146 (Supplement 1): 372.

https://doi.org/10.1182/blood-2025-372

Published: 2025

Journal Articles

Circulating tumor cells (CTCs) improve risk stratification according to the second revision of the international staging system (R2-ISS) and the ims-IMWG consensus genomic staging (CGS) in newly diagnosed multiple myeloma (NDMM): An analysis from the european CTC consortium.

Blood (2025) 146 (Supplement 1): 364.

https://doi.org/10.1182/blood-2025-364

Published: 2025

Journal Articles

Combined assessment of circulating tumor cells (CTCs) and measurable residual disease (MRD) for dynamic risk assessment of patients (Pts) with multiple myeloma (MM)

Blood (2025) 146 (Supplement 1): 494.

https://doi.org/10.1182/blood-2025-494

Published: 2025

Journal Articles

MagnetisMM-6 part 2: A phase 3, open-label, randomized study of elranatamab in combination with daratumumab and lenalidomide vs daratumumab, lenalidomide, and dexamethasone in transplant-ineligible or -deferred patients with newly diagnosed multiple myeloma

Ja Min Byun, Meletios Dimopoulos, Eeman Shaikh, Karen Gogat-Marchant, Nina N. Green, Domenico Cieri, Hang Quach

Blood (2025) 146 (Supplement 1): 5845.

https://doi.org/10.1182/blood-2025-5845

Published: 2025

Journal Articles

Patient-reported outcomes from dreamm-7 and dreamm-8 using the EQ-5D-3L, patient global impression of severity, and patient global impression of change

Suzanne Trudel, Vania Hungria, María-Victoria Mateos, Chee Paul Lin, Julie Byrne, James Parker, Molly Purser, Sandhya Sapra, Farrah Pompilus, Sumita Roy-Ghanta, Giulia Fulci, Joanna Opalinska, Neal Sule, Brandon Kremer, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 5823.

https://doi.org/10.1182/blood-2025-5823

Published: 2025

Journal Articles

Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis

Blood (2025) 146 (Supplement 1): 5820.

https://doi.org/10.1182/blood-2025-5820

Published: 2025

Journal Articles

Safety and efficacy of linvoseltamab (LINVO) combined with anti-CD38 monoclonal antibodies (mAbs) daratumumab (DARA) or isatuximab (ISA) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the multicohort, Phase 1b LINKER-MM2 trial

Meletios Dimopoulos, Sosana Delimpasi, Salomon Manier, Jean-Marie Michot, Enrique Ocio, Samuel Rubinstein, Joselle Cook, Maria Del Carmen Martinez Chamorro, Aurora Breazna, Amishi Dhadwal, Yogita Ghodke, Sheila Masinde, Glenn Kroog, Shawn Sarkaria, Albert Oriol

Blood (2025) 146 (Supplement 1): 2254.

https://doi.org/10.1182/blood-2025-2254

Published: 2025

Journal Articles

Integrated transcriptomic and proteomic analysis of clonal plasma cells from patients with AL amyloidosis

Ourania Theologi, Ioannis Kollias, Kostantina Taouxi, Tina Bagratuni, Alexandra Papadimou, Katerina Chrisostomidou, Nefeli Mavrianou Koutsoukou, Agisilaos Papadopoulos, Christine-Ivy Liacos, Eleni Kalafati, Asimina Papanikolaou, Foteini Theodorakakou, Maria Gavriatopoulou, Evangelos Terpos, Meletios Dimopoulos, Julie Courraud, Efstathios Kastritis

Blood (2025) 146 (Supplement 1): 3931.

https://doi.org/10.1182/blood-2025-3931

Published: 2025

Journal Articles

Comprehensive characterization of multiple myeloma genomes from bone marrow or peripheral blood with a novel clinical assay enables identification of resistance mechanisms

Blood (2025) 146 (Supplement 1): 2586.

https://doi.org/10.1182/blood-2025-2586

Published: 2025

Journal Articles

The novel ims / IMWG high-risk multiple myeloma criteria may omit individuals with renal impairment and adverse disease prognosis

Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Maria Gavriatopoulou, Panagiotis Malandrakis, Vasiliki Spiliopoulou, Foteini Theodorakakou, Eirini Solia, Evangelos Eleutherakis-Papaiakovou, Ilias Katsadouros, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Erasmia Boutakoglou, Konstantinos Giannakas, Evangelos Terpos, Meletios Dimopoulos, Efstathios Kastritis

Blood (2025) 146 (Supplement 1): 3986.

https://doi.org/10.1182/blood-2025-3986

Published: 2025

Journal Articles

Efficacy and safety of recombinant adjuvanted zoster vaccine in patients with monoclonal gammopathies: A prospective study

Vasiliki Spiliopoulou, Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Panagiotis Malandrakis, Evangelos Eleutherakis-Papaiakovou, Eirini Solia, Ilias Katsadouros, Foteini Theodorakakou, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Evangelos Terpos, Efstathios Kastritis, Meletios Dimopoulos, Maria Gavriatopoulou

Blood (2025) 146 (Supplement 1): 3985.

https://doi.org/10.1182/blood-2025-3985

Published: 2025

Journal Articles

Characterization of NDMM patients treated with daratumumab, lenalidomide, bortezomib and dexamethasone who fail to achieve a VGPR or have early progression

Jonathan Kaufman, Efstathios Kastritis, Nisha Joseph, Maria Gavriatopoulou, Lilly Gu, Craig Hofmeister, Vikas Gupta, Evangelos Terpos, Ajay Nooka, Sagar Lonial, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 407.

https://doi.org/10.1182/blood-2025-407

Published: 2025

Journal Articles

Validation of the new ims/IMWG consensus genomic staging (CGS) of high-risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients

Efstathios Kastritis, Maria Gavriatopoulou, Foteini Theodorakakou, Eirini Solia, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Nikolaos Kanellias, Evangelos Eleutherakis Papaiakovou, Magdalini Migkou, Vasiliki Spiliopoulou, Ilias Katsadouros, Stavroula Giannouli, Panagiotis Tsirigotis, Asimina Papanikolaou, Despina Fotiou, Konstantinos Giannakas, Erasmia Boutakoglou, Evangelos Terpos, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 923.

https://doi.org/10.1182/blood-2025-923

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

An open-label rollover study to assess the long-term safety of ixazomib

Nanopore sequencing-based profiling of circular RNAs in multiple myeloma uncovers circNFATC3 as a promising prognostic biomarker

Novel criteria for evaluating early treatment response with whole body magnetic resonance imaging and prognostic implications in patients with newly diagnosed multiple myeloma

Impact of tumor burden on the risk of cytokine release syndrome (CRS) in patients with multiple myeloma treated with elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) in the MagnetisMM-6 trial

Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients

Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study

Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age

Circulating tumor cells (CTCs) improve risk stratification according to the second revision of the international staging system (R2-ISS) and the ims-IMWG consensus genomic staging (CGS) in newly diagnosed multiple myeloma (NDMM): An analysis from the european CTC consortium.

Combined assessment of circulating tumor cells (CTCs) and measurable residual disease (MRD) for dynamic risk assessment of patients (Pts) with multiple myeloma (MM)

MagnetisMM-6 part 2: A phase 3, open-label, randomized study of elranatamab in combination with daratumumab and lenalidomide vs daratumumab, lenalidomide, and dexamethasone in transplant-ineligible or -deferred patients with newly diagnosed multiple myeloma

Patient-reported outcomes from dreamm-7 and dreamm-8 using the EQ-5D-3L, patient global impression of severity, and patient global impression of change

Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis

Safety and efficacy of linvoseltamab (LINVO) combined with anti-CD38 monoclonal antibodies (mAbs) daratumumab (DARA) or isatuximab (ISA) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the multicohort, Phase 1b LINKER-MM2 trial

Integrated transcriptomic and proteomic analysis of clonal plasma cells from patients with AL amyloidosis

Comprehensive characterization of multiple myeloma genomes from bone marrow or peripheral blood with a novel clinical assay enables identification of resistance mechanisms

The novel ims / IMWG high-risk multiple myeloma criteria may omit individuals with renal impairment and adverse disease prognosis

Efficacy and safety of recombinant adjuvanted zoster vaccine in patients with monoclonal gammopathies: A prospective study

Characterization of NDMM patients treated with daratumumab, lenalidomide, bortezomib and dexamethasone who fail to achieve a VGPR or have early progression

Validation of the new ims/IMWG consensus genomic staging (CGS) of high-risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only